BombardierCGladmanDDUrowitzMBCaronDChangCH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum1992; 35: 630–640.
2.
SunJZhangHJiYet al.Efficacy and safety of cyclophosphamide combined with mycophenolate mofetil for induction treatment of class IV lupus nephritis. Int J Clin Exp Med2015; 8: 21572–21578.
3.
Zhang H, Liu Z, Zhou M, et al. Multitarget therapy for maintenance treatment of lupus nephritis. J Am Soc Nephrol. Epub ahead of print 31 July 2017. DOI: 10.1681/ASN-2017-030263.
4.
SchousboeJTKochAEChangRW. Chronic lupus peritonitis with ascites: Review of the literature with a case report. Semin Arthritis Rheum1988; 18: 121–126.
5.
ItoHNanamiyaWKurodaNet al.Chronic lupus peritonitis with massive ascites at elderly onset: Case report and review of the literature. Intern Med2002; 41: 1056–1061.
6.
GummertJFIkonenTMorrisRE. Newer immunosuppressive drugs: A review. J Am Soc Nephrol1999; 10: 1366–1380.
7.
KusunokiYTanakaNKanekoKYamamotoTEndoHKawaiS. Tacrolimus therapy for systemic lupus erythematosus without renal involvement: A preliminary retrospective study. Mod Rheumatol2009; 19: 616–621.
8.
MokCCToCHYuKLHoLY. Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: A 12-month prospective study. Lupus2013; 22: 1135–1141.
9.
IkeuchiHHiromuraKTakahashiSet al.Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolate mofetil and a steroid in patients with active lupus nephritis. Mod Rheumatol2014; 24: 618–625.
10.
LiuZZhangHLiuZet al.Multitarget therapy for induction treatment of lupus nephritis: A randomized trial. Ann Intern Med2015; 162: 18–26.
11.
OhJSKimYGLeeSGLeeCKYooB. Successful treatment of recurrent lupus enteritis with rituximab. Lupus2010; 19: 220–222.
12.
BitranJMcShaneDEllmanMH. Arthritis rounds: Ascites as the major manifestation of systemic lupus erythematosus. Arthritis Rheum1976; 19: 782–785.
